-
The field of children's medicine is attracting major pharmaceutical companies to accelerate their deployment!
Time of Update: 2022-01-25
For another example, in the field of drugs that are clinically scarce for children with rare diseases in China, on December 17, 2021, Sunflower Pharmaceuticals and Dr.
, certain support from policy and economic levels has been given, which has increased the confidence of enterprises in R&D and production of children's medicines .
-
Xianju Pharmaceutical's Flumazenil Injection Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2022-01-25
On January 11, Xianju Pharmaceutical announced that it had recently received the "Approval Notice for Supplementary Drug Application" for Flumazenil Injection approved and issued by the State Food and Drug Administration.
Flumazenil Injection passed the same generic drug.
-
Over-evaluation of multiple products, the domestic antithrombotic drug market still has a lot of room for growth
Time of Update: 2022-01-25
For example, Sihuan Pharmaceutical recently announced that the antithrombotic drug ticagrelor tablets (60 mg and 90 mg) developed by the group have been approved for drug registration issued by the China National Medical Products Administration, which is deemed to have the same quality and efficacy as a generic drug.
-
NMPA issued an announcement to stop the production, sales and use of Lianbizhi injection from now on
Time of Update: 2022-01-25
For products that have been marketed, the holder of the drug marketing authorization is responsible for the recall, and the recalled products are supervised and destroyed by the local provincial drug supervision and administration department or take other measures such as harmless treatment in accordance with the law .
-
Will the breakout of new pharmaceutical stocks become the norm?
Time of Update: 2022-01-25
On January 7th, Asieris Pharmaceuticals, a new stock listed on the Science and Technology Innovation Board, broke its offering at the opening and fell sharply by 12.
-
Hengrui Medicine's Haitrombopag Ethanolamine Tablets Obtained the Qualification of US FDA Clinical Trial
Time of Update: 2022-01-25
Hetrombopag ethanolamine tablets were approved by the State Drug Administration to conduct clinical trials for the treatment of aplastic anemia in December 2017 (announcement number: Lin 2017-080), and in August 2019, they were approved to carry out tumor chemotherapy-induced thrombocytopenia The clinical trial of CIT (Announcement No.
-
The listing application of Huachun Bio/Sinopharm Dezhong Traditional Chinese Medicine Class 1 new drug, Prince Shenyue Capsule, was accepted
Time of Update: 2022-01-25
Sales of terminal nervous system Chinese patent medicines in physical pharmacies in Chinese cities (unit: 10,000 yuan)Source: Minet.
2020 China's urban physical pharmacy terminal nervous system Chinese patent medicine TOP5 productsSource: Minet.
-
The first clinical report of TIGIT monoclonal antibody of Kangfang Bio
Time of Update: 2022-01-25
Source: CDE official websiteAK127 is a TIGIT monoclonal antibody independently developed by the company.
According to the Insight database, there are 7 TIGIT monoclonal antibodies and 4 double-antibodies under development in China.
At present, there are 9 TIGIT monoclonal antibody projects in clinical development in China .
-
Dong'e Ejiao Chairman Han Yuewei and President Gao Dengfeng resign
Time of Update: 2022-01-25
Gao Dengfeng applied for his resignation as the company's president and legal representative .
Gao Dengfeng will continue to serve as a director of the tenth board of directors of the company .
-
In 2022, which segments of the pharmaceutical industry are worthy of seizing opportunities?
Time of Update: 2022-01-25
The fund manager of China Asset Management believes that in the entire investment strategy, it is worth paying attention to these pharmaceutical companies with pricing power, and is optimistic about 4 directions: First, biomedicine at the manufacturing end and upstream equipment, reagents and consumables of biomedicine Second, the field of medical consumer goods, such as specialized medical services, consumer medical consumables and traditional Chinese medicine products, etc.
-
In 2021, a large number of domestic innovative drugs will be terminated
Time of Update: 2022-01-25
On December 28, Fosun Pharma announced that its subsidiary Jiangsu Wanbang had decided to terminate the clinical trial and subsequent development of the SGLT-2 inhibitor vanpagliflozin .
-
Nearly 80% of the new total market capitalization of pharmaceutical companies has increased compared to when they were first listed, with 2 companies increasing by more than 10,000%
Time of Update: 2022-01-25
For example, on the product side, Pien Tze Huang Pharma has invested heavily in innovative research and development, made efforts to master the core technologies of the industrial chain, and strengthened cooperation with many universities and scientific research institutions at home and abroad.
-
In 2022, personnel changes in pharmaceutical companies are becoming more frequent
Time of Update: 2022-01-25
On January 6, Buchang Pharmaceutical announced that Liu Luxiang applied for his resignation as vice president of the company due to personal reasons, and would not hold any position in the company after resignation.
-
Sialon Pharmaceutical's Milrinone Injection Obtained Approval for Supplemental Drug Application
Time of Update: 2022-01-25
On January 10, Sailong Pharmaceutical Group Co.
announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Co.
, has recently obtained the “Approval for Supplementary Drug Application for Milrinone Injection” approved and issued by the State Drug Administration.
-
27 domestic innovative drugs will be launched in 2021, reaching new heights
Time of Update: 2022-01-25
Among them, six pharmaceutical companies, including Hengrui Pharmaceutical, Fosun Pharmaceutical, Mindray Medical, Junshi Bio, Shanghai Pharmaceuticals, and Kelun Pharmaceutical, have invested more than 1 billion yuan in research and development .
-
CDE issued 5 guiding principles involving traditional Chinese medicine, improved new drugs, innovative drugs, etc.
Time of Update: 2022-01-25
The details are as follows: Under the deployment of the State Drug Administration, the Center for Drug Evaluation organized the formulation of the "Technical Guidelines for the Study of Samples for Toxicology Research of New Chinese Medicines (for Trial Implementation)" (see attachment) .
-
Ambroxol hydrochloride oral solution, a subsidiary of Hengrui Medicine, was approved for marketing
Time of Update: 2022-01-25
The approved drug Ambroxol Hydrochloride Oral Liquid can increase the secretion of mucous glands in the respiratory tract and reduce the secretion of mucous glands, thereby reducing the viscosity of sputum, and at the same time promoting the secretion of pulmonary surfactant, increasing the movement of bronchial cilia to make sputum easier to cough up, suitable for For acute and chronic bronchitis caused by thick sputum, difficult expectoration .
-
The wave of innovative drugs is approaching, who can take the lead in the internationalization of the sea of stars?
Time of Update: 2022-01-25
In his sharing, Liu Zexu said that if the proportion of domestic innovative drugs in the pharmaceutical industry increases from 8% to 30% by 2025, the market increment space for the entire innovative drug industry will exceed 600 billion yuan in the future .
-
Ascletis submits clinical application for oral PD-L1 small molecule inhibitor in the United States
Time of Update: 2022-01-25
According to Ascletis in a press release, ASC61 is a potent and highly selective oral PD-L1 small-molecule inhibitor developed by the company.
-
Eli Lilly's "baricitinib" new indication was listed in domestic reports
Time of Update: 2022-01-25
In July 2019, the State Drug Administration approved the marketing of baricitinib tablets for the treatment of moderately to severely active rheumatoid arthritis in adults, with the trade name of elemin .
